RIGEL PHARMACEUTICALS INC (RIGL) Stock Income Statement
NASDAQ:RIGL - Nasdaq - US7665597024 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 203.08M | 179.28M | 116.88M | 120.20M | 149.20M | |||
| Cost Of Goods | 21.03M | 18.65M | 7.11M | 1.70M | 1.10M | |||
| Gross Profit | 182.05M | 160.63M | 109.77M | 118.50M | 148.20M | |||
| Operating Expenses | 138.12M | 136.44M | 130.26M | 172.80M | 157.10M | |||
| Research and Development | 25.79M | 23.38M | 24.52M | 60.30M | 65.20M | |||
| Selling, General, and Administrative Expenses | 112.33M | 113.06M | 105.74M | 112.50M | 91.90M | |||
| Operating Income | 43.93M | 24.19M | -20.49M | -54.30M | -9.00M | |||
| Interest Income/Expense | -5.81M | -5.83M | -4.60M | -3.00M | -4.80M | |||
| Non Recurring Items | N/A | 0.00 | N/A | -1.30M | -3.50M | |||
| Income Before Taxes | 38.12M | 18.37M | -25.09M | -58.60M | -17.30M | |||
| Income Tax | N/A | 881.00K | N/A | 0.00 | 600.00K | |||
| Net Income | 37.18M | 17.48M | -25.09M | -58.60M | -17.90M | |||
| EBITDA | 46.36M | 26.42M | -19.25M | -53.30M | -7.84M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 2.07 | 0.99 | -1.44 | -0.34 | -0.11 | |||
| Non GAAP EPS | 2.07 | 0.94 | -1.50 | -3.40 | -1.10 | |||
| Statistics | ||||||||
| Gross Profit Margin | 89.64% | 89.60% | 93.92% | 98.59% | 99.33% | |||
| Profit Margin | 18.31% | 9.75% | -21.47% | -48.75% | -12.00% | |||
| Operating Profit Margin | 21.63% | 13.49% | -17.53% | -45.17% | -6.03% | |||
All data in USD